Microbiome therapeutics:exploring the present scenario and challenges  

作　　者：Monika Yadav Nar Singh Chauhan 

机构地区：[1]Department of Biochemistry,Maharshi Dayanand University,Rohtak,Haryana,India

出　　处：《Gastroenterology Report》2022年第1期18-36,共19页胃肠病学报道（英文）

基　　金：the MDU RKF fund for financial support vide MDU/DSW/339.

摘　　要：Human gut-microbiome explorations have enriched our understanding ofmicrobial colonization,maturation,and dysbiosis in health-and-disease subsets.The enormousmetabolic potential of gutmicrobes and their role in themaintenance of human health is emerging,with new avenues to use themas therapeutic agents to overcome human disorders.Microbiome therapeutics are aimed at engineering the gutmicrobiome using additive,subtractive,ormodulatory therapy with an application of native or engineeredmicrobes,antibiotics,bacteriophages,and bacteriocins.This approach could overcome the limitation of conventional therapeutics by providing personalized,harmonized,reliable,and sustainable treatment.Its huge economic potential has been shown in the global therapeuticsmarket.Despite the therapeutic and economical potential,microbiome therapeutics is still in the developing stage and is facing various technical and administrative issues that require research attention.This review aims to address the current knowledge and landscape ofmicrobiome therapeutics,provides an overview of existing health-and-disease applications,and discusses the potential future directions ofmicrobiomemodulations.

关 键 词：microbiome therapeutics human microbiome engineered microbiome PROBIOTICS PREBIOTICS fecal microbiome transplantation 

分 类 号：R57[医药卫生—消化系统]